May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS

RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer programs, and GSK/Ionis's buried hepatitis B 'functional cure.'Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, RevolutionMedicines, ivonescimab, Akeso, Summit Therapeutics, Pfizer, Innovent Biologics,Eli Lilly, ASCO 2026, pancreatic cancer, KRAS, RAS, lung cancer, bepirovirsen,GSK, Ionis, hepatitis B, Braftovi, Lorbrena, Talzenna, Erleada, Zepbound,Foundayo, MannKind, Afrezza, Incyte, Monjuvi, DLBCL, BMS, Retevmo, Allogene,Lilly, Novo Nordisk, Merck, J&J